Articles
1 November 2005

Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody–Associated Small-Vessel Vasculitis

Publication: Annals of Internal Medicine
Volume 143, Number 9

Abstract

Background:

Predictors of treatment resistance and relapse have not been well described in antineutrophil cytoplasmic antibody (ANCA)–associated small-vessel vasculitis.

Objective:

To identify clinical, pathologic, and serologic predictors of treatment resistance and relapse in a community-based cohort of patients with ANCA-associated vasculitis.

Design:

Cohort of patients identified at or near the time of biopsy diagnosis and followed as clinically indicated.

Setting:

The Glomerular Disease Collaborative Network.

Patients:

350 patients who received a new diagnosis of ANCA-associated vasculitis between 1985 and 2003 and were followed for a median of 49 months.

Measurements:

Patients were categorized according to whether they had antiproteinase-3 (anti-PR3) antibodies or antimyeloperoxidase (anti-MPO) antibodies. Organ involvement was determined by biopsy or by well-defined clinical criteria. Treatment resistance was defined as progressive decline in kidney function with active urine sediment or the persistence or appearance of extrarenal manifestations. Relapse was defined as the time to the resurgence of vasculitic symptoms.

Results:

Treatment resistance affected 23% of 334 treated patients and was associated with female sex, black ethnicity, and presentation with severe kidney disease (odds ratio per serum creatinine elevation of 100 µmol/L [1.13 mg/dL], 1.28 [95% CI, 1.16 to 1.39]). The following factors were associated with relapse in 258 (77%) patients who attained remission: seropositivity for anti-PR3 antibodies (hazard ratio, 1.87 [CI, 1.11 to 3.14]) and disease of the lung (hazard ratio, 1.71 [CI, 1.04 to 2.81]) or upper respiratory tract (hazard ratio, 1.73 [CI, 1.04 to 2.88]). Relapses occurred in 26% of patients with no risk factors versus 73% of patients with all 3 risk factors (hazard ratio, 3.7 [CI, 1.4 to 9.7]). Among 143 patients attaining remission who subsequently stopped all immunosuppressant therapy, relapse rates were similar for those who had received cyclophosphamide therapy for 6 months or less (34%) compared with those treated for a longer duration (35%), even after adjusting for risk factors for relapse (hazard ratio, 1.41 [CI, 0.80 to 2.50]).

Limitations:

The cohort mostly included patients with biopsy-proven kidney disease. Patients were not followed with uniform treatment protocols, and only limited information about their clinical course before diagnosis was available.

Conclusions:

Female or black patients, or those with severe kidney disease, may be resistant to initial treatment more often than other patients with ANCA-associated small-vessel vasculitis. Increased risk for relapse appears to be related to the presence of lung or upper airway disease and anti-PR3 antibody seropositivity.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Jennette JCFalk RJAndrassy KBacon PAChurg JGross WLet al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-92. [PMID: 8129773]
2.
Jennette JCWilkman ASFalk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135:921-30. [PMID: 2683800]
3.
Falk RJHogan SCarey TSJennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med. 1990;113:656-63. [PMID: 2221646]
4.
Hogan SLNachman PHWilkman ASJennette JCFalk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23-32. [PMID: 8808106]
5.
de Groot KAdu DSavage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16:2018-27. [PMID: 11572891]
6.
Briedigkeit LKettritz RGobel UNatusch R. Prognostic factors in Wegener's granulomatosis. Postgrad Med J. 1993;69:856-61. [PMID: 8290430]
7.
Nachman PHHogan SLJennette JCFalk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33-9. [PMID: 8808107]
8.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-61. [PMID: 15673801]
9.
Savage COWinearls CGEvans DJRees AJLockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985;56:467-83. [PMID: 4048389]
10.
Reinhold-Keller EFink COHerlyn KGross WLDe Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum. 2002;47:326-32. [PMID: 12115164]
11.
Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med. 2005;352:330-2. [PMID: 15673799]
12.
Hagen ECBallieux BEvan Es LADaha MRvan der Woude FJ. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood. 1993;81:1996-2002. [PMID: 8471761]
13.
Levey ASBosch JPLewis JBGreene TRogers NRoth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70. [PMID: 10075613]
14.
Levey ASGreen TKusek JWBeck GJMDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol. 2000;11:155A.
15.
Allison PD. Competing Risks. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Publishing; 1995:29-60, 185-209.
16.
Kalbfleisch JDPrentice RLeds. The Statistical Analysis of Failure Time Data. 2nd ed. Hoboken, NJ: J Wiley; 2002:1-29, 196-199, 247-77.
17.
Pepe MSMori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12:737-51. [PMID: 8516591]
18.
Gooley TALeisenring WCrowley JStorer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706. [PMID: 10204198]
19.
Therneau TMGrambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer Publishing; 2000.
20.
Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707-23. [PMID: 7481205]
21.
Jayne DRasmussen NAndrassy KBacon PTervaert JWDadoniene Jet al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44. [PMID: 12840090]
22.
Guillevin LCordier JFLhote FCohen PJarrousse BRoyer Iet al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40:2187-98. [PMID: 9416856]
23.
Guillevin LCohen PMahr AArene JPMouthon LPuechal Xet al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49:93-100. [PMID: 12579599]
24.
Koldingsnes WNossent JC. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol. 2003;30:80-8. [PMID: 12508394]
25.
Bajema IMHagen ECHermans JNoel LHWaldherr RFerrario Fet al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751-8. [PMID: 10571783]
26.
Booth ADAlmond MKBurns AEllis PGaskin GNeild GHet al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776-84. [PMID: 12666064]
27.
van der Woude FJRasmussen NLobatto SWiik APermin Hvan Es LAet al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985;1:425-9. [PMID: 2857806]
28.
Kerr GSFleisher TAHallahan CWLeavitt RYFauci ASHoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. Adv Exp Med Biol. 1993;336:411-4. [PMID: 8296645]
29.
Davenport ALock RJWallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol. 1995;15:201-7. [PMID: 7618644]
30.
Tervaert JWHuitema MGHene RJSluiter WJThe THvan der Hem GKet al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet. 1990;336:709-11. [PMID: 1975893]
31.
Segelmark MPhillips BDHogan SLFalk RJJennette JC. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis. Clin Diagn Lab Immunol. 2003;10:769-74. [PMID: 12965902]
32.
Girard TMahr ANoel LHCordier JFLesavre PAndre MHet al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford). 2001;40:147-51. [PMID: 11257150]
33.
Kyndt XReumaux DBridoux FTribout BBataille PHachulla Eet al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med. 1999;106:527-33. [PMID: 10335724]
34.
Tervaert JWStegeman CAKallenberg CG. Serial ANCA testing is useful in monitoring disease activity of patients with ANCA-associated vasculitides. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:241-5. [PMID: 8946592]
35.
De'Oliviera JGaskin GDash ARees AJPusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis. 1995;25:380-9. [PMID: 7872315]
36.
Han WKChoi HKRoth RMMcCluskey RTNiles JL. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int. 2003;63:1079-85. [PMID: 12631091]
37.
Langford CA. Antineutrophil cytoplasmic antibodies should not be used to guide treatment in Wegener's granulomatosis [Editorial]. Clin Exp Rheumatol. 2004;22:S3-6. [PMID: 15675126]
38.
Boomsma MMStegeman CAvan der Leij MJOost WHermans JKallenberg CGet al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43:2025-33. [PMID: 11014352]
39.
Jayne DRGaskin GPusey CDLockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM. 1995;88:127-33. [PMID: 7704563]
40.
Stegeman CATervaert JWSluiter WJManson WLde Jong PEKallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12-7. [PMID: 8250451]
41.
Popa ERStegeman CABos NAKallenberg CGTervaert JW. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol. 2003;132:496-504. [PMID: 12780698]
42.
Guillevin LLhote FCohen PJarrousse BLortholary OGenereau Tet al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38:1638-45. [PMID: 7488285]
43.
Fauci ASHaynes BKatz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978;89:660-76. [PMID: 31121]
44.
Langford CATalar-Williams CBarron KSSneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114:463-9. [PMID: 12727579]
45.
Langford CATalar-Williams CSneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43:1836-40. [PMID: 10943874]
46.
Metzler CFink CLamprecht PGross WLReinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford). 2004;43:315-20. [PMID: 14963200]
47.
Nowack RGobel UKlooker PHergesell OAndrassy Kvan der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999;10:1965-71. [PMID: 10477149]
48.
Franssen CFStegeman CAKallenberg CGGans RODe Jong PEHoorntje SJet al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int. 2000;57:2195-206. [PMID: 10844589]
49.
Watts RALane SEScott DGKoldingsnes WNossent HGonzalez-Gay MAet al. Epidemiology of vasculitis in Europe [Letter]. Ann Rheum Dis. 2001;60:1156-7. [PMID: 11760724]
50.
Watts RAScott DG. Epidemiology of the vasculitides. Curr Opin Rheumatol. 2003;15:11-6. [PMID: 12496504]
51.
Cotch MFHoffman GSYerg DEKaufman GITargonski PKaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996;39:87-92. [PMID: 8546743]
52.
Lim LCTaylor JG 3rdSchmitz JLFolds JDWilkman ASFalk RJet al. Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serology. Comparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits. Am J Clin Pathol. 1999;111:363-9. [PMID: 10078112]
53.
Klemmer PJChalermskulrat WReif MSHogan SLHenke DCFalk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42:1149-53. [PMID: 14655185]
54.
Gaskin GJayne DREuropean Vasculitis Study Group. Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis [Abstract]. J Am Soc Nephrol. 2002;13:2A-3A.

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 143Number 91 November 2005
Pages: 621 - 631

History

Published online: 1 November 2005
Published in issue: 1 November 2005

Keywords

Authors

Affiliations

Susan L. Hogan, PhD, MPH
From the University of North Carolina, Chapel Hill, North Carolina.
Ronald J. Falk, MD
From the University of North Carolina, Chapel Hill, North Carolina.
Hyunsook Chin, MPH
From the University of North Carolina, Chapel Hill, North Carolina.
Jianwen Cai, PhD
From the University of North Carolina, Chapel Hill, North Carolina.
Caroline E. Jennette, MSW
From the University of North Carolina, Chapel Hill, North Carolina.
J. Charles Jennette, MD
From the University of North Carolina, Chapel Hill, North Carolina.
Patrick H. Nachman, MD
From the University of North Carolina, Chapel Hill, North Carolina.
Acknowledgments: The authors thank the physicians and medical staff who participate in the Glomerular Disease Collaborative Network and the patients who made this study possible.
Grant Support: In part by a grant from the National Institutes of Health, National Institute of Diabetes & Digestive & Kidney Diseases (program project number P01-DK58335).
Disclosures: Grants received: S.L. Hogan (National Institutes of Health), R.J. Falk (National Institutes of Health), C.E. Jennette (National Institutes of Health), J.C. Jennette (National Institutes of Health), P.H. Nachman (National Institutes of Health).
Corresponding Author: Susan L. Hogan, PhD, MPH, Division of Nephrology and Hypertension, Department of Medicine, UNC Kidney Center, CB 7156, 7024B Burnett-Womack, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7156; e-mail, [email protected].
Current Author Addresses: Drs. Hogan, Falk, and Nachman, Ms. Chin, and Ms. Jennette: Division of Nephrology and Hypertension, Department of Medicine, UNC Kidney Center, CB 7156, 7024B Burnett-Womack, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7156.
Dr. Cai: School of Public Health, CB 7400, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7400.
Dr. Jennette: Department of Pathology and Laboratory Medicine, CB 7525, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7525.
Author Contributions: Conception and design: S.L. Hogan, R.J. Falk, J.C. Jennette, P.H. Nachman.
Analysis and interpretation of the data: S.L. Hogan, R.J. Falk, H. Chin, J. Cai, J.C. Jennette, P.H. Nachman.
Drafting of the article: S.L. Hogan, R.J. Falk, J.C. Jennette, P.H. Nachman.
Critical revision of the article for important intellectual content: S.L. Hogan, R.J. Falk, H. Chin, J. Cai, C.E. Jennette, J.C. Jennette, P.H. Nachman.
Final approval of the article: S.L. Hogan, R.J. Falk, H. Chin, J. Cai, C.E. Jennette, J.C. Jennette, P.H. Nachman.
Provision of study materials or patients: R.J. Falk, P.H. Nachman.
Statistical expertise: S.L. Hogan, H. Chin, J. Cai.
Obtaining of funding: S.L. Hogan, R.J. Falk.
Administrative, technical, or logistic support: S.L. Hogan, R.J. Falk, J. Cai, C.E. Jennette.
Collection and assembly of data: S.L. Hogan, R.J. Falk, C.E. Jennette, P.H. Nachman.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Susan L. Hogan, Ronald J. Falk, Hyunsook Chin, et al. Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody–Associated Small-Vessel Vasculitis. Ann Intern Med.2005;143:621-631. [Epub 1 November 2005]. doi:10.7326/0003-4819-143-9-200511010-00005

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media